Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00166036 · ClinicalTrials.gov registry record · Phase 2

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

A Phase 2 study of Diabetes Mellitus and Hypercholesterolemia, sponsored by Emory University.

Completed
Registry status
Phase 2
Development phase
36
Enrollment target
1
Study location

NCT00166036 is a Phase 2 study of Diabetes Mellitus and Hypercholesterolemia that has completed, run by Emory University. The registered enrollment target is 36 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00166036, a Phase 2 study of Diabetes Mellitus and Hypercholesterolemia, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 2
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

Thirty-six subjects with hyperlipidemia and metabolic syndrome and/or diabetes were randomized in a double-blind manner to either pravastatin 80 mg or atorvastatin 10 mg daily. Oxidative stress (dROMs assay that measures lipid hydroperoxides, plasma thiobarbituric acid reactive substances \[TBARS\], and aminothiol levels) and brachial artery flow-mediated dilation (FMD) were measured at baseline and after 12 weeks of statin therapy.

Interventions

  • DRUG Atorvastatin
  • DRUG Pravastatin

Study Locations (1)

Georgia

  • Emory University Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2004-09
Est. Completion 2009-04
Phase Phase 2

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT00166036

The ClinicalTrials.gov registry entry for NCT00166036 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Atorvastatin is the first listed.

NCT00166036 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT00166036 about?

NCT00166036 is a clinical study titled "Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells". Thirty-six subjects with hyperlipidemia and metabolic syndrome and/or diabetes were randomized in a double-blind manner to either pravastatin 80 mg or atorvastatin 10 mg daily. Oxidative stress (dROMs assay that measures lipid hydroperoxides, plasma thiobarbituric acid reactive substances \[TBARS\],...

What is the current status of trial NCT00166036?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2004-09. Estimated completion is 2009-04.

What conditions does trial NCT00166036 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Hypercholesterolemia, Metabolic Syndrome X.

What interventions are being tested in trial NCT00166036?

The interventions under investigation include: Atorvastatin (DRUG), Pravastatin (DRUG).

Who is sponsoring clinical trial NCT00166036?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00166036 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.